Power calculations were not reported as having been used to determine the sample size. Overall, 1,004 patients were included in the study from 7 countries (Australia, Canada, Finland, France, Germany, Spain, and the UK). A subpopulation of 445 patients was analysed in this study. Half of the patients continued with the regimen with inhaled corticosteroids and/or inhaled B2-agonists while the other half were administered budesonide and/or terbutaline via Turbuhaler. Six patients in each group were excluded from the initial sample. The average age of the patients in the pMDI group (n=215) was 41 years versus 40 years in the Turbuhaler group (N=218).